Asiaticobdella Hirudin Variant 2
Putative hirudin variant from the salivary transcriptome of the African medicinal leech Asiaticobdella fenestrata — Schulz 2025 recombinant characterization in coagulation assays.
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Putative hirudin variant from the salivary transcriptome of the African medicinal leech Asiaticobdella fenestrata — Schulz 2025 recombinant characterization in coagulation assays.
- Evidence level
- In vitro
- Drug vs leech
- Recombinant (genetically expressed)
- Safety domains
- Bleeding
Clinical translation limit
Asiaticobdella hirudin-2's in vitro thrombin-inhibition activity does NOT establish clinical efficacy. No FDA-approved derivative exists; A. fenestrata is not on the FDA K040187 cleared device species list.
Molecular Profile
- Category
- Anticoagulant
- Evidence tier
- Preclinical
- Source species
- Asiaticobdella fenestrata
- Discovered
- 2025 · Schulz L et al.
Biological Targets
- → thrombin (predicted, by hirudin homology)
Key Citations
- Schulz L et al. (2025), Parasitol Res · PMID 41198932
External Resources
Related Anticoagulant Compounds
Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
Antistasin
Factor Xa inhibitor — prototype molecule that inspired the entire DOAC drug class (rivaroxaban, apixaban).
Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.